Bumble Inc vs Boston Scientific Corporation — how do they compare? Bumble Inc trades at $2.62 (market cap $366.87M), while Boston Scientific Corporation trades at $51.28 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 202.2× Bumble Inc's market cap, and Boston Scientific Corporation is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| BMBL | BSX | |
|---|---|---|
Market Cap | $366.87M | $74.19B |
Sector | Technology | Health |
52-Week High | $7.17 | $108.14 |
52-Week Low | $2.70 | $42.63 |
Enterprise Value | $672.73M | $86.27B |
Signals from Pluang's Aura AI — not financial advice
Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.
The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
Trailing returns across standard periods
Latest headlines on both assets
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →